You are here: Industry Insights > Dupixent

News List

FDA approves Regeneron, Sanofi's Dupixent for asthma treatment biospectrumasia
November 26, 2018
The FDA approves Regeneron Pharmaceuticals and development partner Sanofi's DUPIXENT (dupilumab) as add-on maintenance therapy in patients with
FDA grants priority review status for Dupixent in atopic dermatitis pharmaceutical-technology
November 10, 2018
Sanofi and Regeneron Pharmaceuticals have received priority review status from the US Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis.
Sanofi and Regeneron’s Dupixent gets more positive feedback from US FDA expressbpd
November 08, 2018
Dupixent was launched in the US in April 2017 for the treatment of moderate-to-severe eczema
Priority review for Sanofi, Regeneron’s Dupixent pharmatimes
November 08, 2018
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials pharmatimes
November 01, 2018
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps (CRSwNP) met all ...
Sanofi's Dupixent set for $2.5B in peak asthma sales after scoring winning label fiercepharma
October 23, 2018
Even as its diabetes unit struggles, Sanofi has made strides on the market with Dupixent since launching last year in eczema.
FDA approves Regeneron, Sanofi's Dupixent for asthma treatment biospectrum
October 23, 2018
Regeneron and Sanofi recognize that DUPIXENT can only help those uncontrolled moderate-to-severe AD patients that were prescribed the medicine if they can both access the medicine and use it properly.
Sanofi, Regeneron’s Dupixent shines in rhinosinusitis with nasal polyps trials October 19, 2018
Sanofi and Regeneron have unveiled top-line data showing that two late-stage studies of Dupixent in adults with inadequately-controlled chronic rhinosinusitis...
EU reviews for Sanofi’s Dupixent, cemiplimab pharmatimes
July 19, 2018
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Sanofi files Dupixent for severe asthma pharmatimes
March 05, 2018
US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.

Previous page 1 2 3 4 5 Next page